190 related articles for article (PubMed ID: 18811920)
1. Decline of plasma 5alpha-dihydrotestosterone (DHT) levels upon testosterone administration to elderly men with subnormal plasma testosterone and high DHT levels.
Gooren LJ; Saad F; Haide A; Yassin A
Andrologia; 2008 Oct; 40(5):298-302. PubMed ID: 18811920
[TBL] [Abstract][Full Text] [Related]
2. Plasma levels of dihydrotestosterone remain in the normal range in men treated with long-acting parenteral testosterone undecanoate.
Yassin AA; Saad F
Andrologia; 2007 Oct; 39(5):181-4. PubMed ID: 17714216
[TBL] [Abstract][Full Text] [Related]
3. Effects of various modes of androgen substitution therapy on erythropoiesis.
Jockenhövel F; Vogel E; Reinhardt W; Reinwein D
Eur J Med Res; 1997 Jul; 2(7):293-8. PubMed ID: 9233903
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and safety of long-acting testosterone undecanoate injections in hypogonadal men: an 84-week phase III clinical trial.
Wang C; Harnett M; Dobs AS; Swerdloff RS
J Androl; 2010; 31(5):457-65. PubMed ID: 20133964
[TBL] [Abstract][Full Text] [Related]
5. Transdermal testosterone therapy in the treatment of male hypogonadism.
Ahmed SR; Boucher AE; Manni A; Santen RJ; Bartholomew M; Demers LM
J Clin Endocrinol Metab; 1988 Mar; 66(3):546-51. PubMed ID: 3350906
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of transdermal testosterone gel in hypogonadal men: application of gel at one site versus four sites: a General Clinical Research Center Study.
Wang C; Berman N; Longstreth JA; Chuapoco B; Hull L; Steiner B; Faulkner S; Dudley RE; Swerdloff RS
J Clin Endocrinol Metab; 2000 Mar; 85(3):964-9. PubMed ID: 10720024
[TBL] [Abstract][Full Text] [Related]
7. Enhanced transdermal delivery of testosterone across nonscrotal skin produces physiological concentrations of testosterone and its metabolites in hypogonadal men.
Meikle AW; Mazer NA; Moellmer JF; Stringham JD; Tolman KG; Sanders SW; Odell WD
J Clin Endocrinol Metab; 1992 Mar; 74(3):623-8. PubMed ID: 1740497
[TBL] [Abstract][Full Text] [Related]
8. C-reactive protein levels and ageing male symptoms in hypogonadal men treated with testosterone supplementation.
Giltay EJ; Haider A; Saad F; Gooren LJ
Andrologia; 2008 Dec; 40(6):398-400. PubMed ID: 19032692
[TBL] [Abstract][Full Text] [Related]
9. Representativeness of a single point plasma testosterone level for the long term hormonal milieu in men.
Vermeulen A; Verdonck G
J Clin Endocrinol Metab; 1992 Apr; 74(4):939-42. PubMed ID: 1548361
[TBL] [Abstract][Full Text] [Related]
10. Oral testosterone in oil: pharmacokinetic effects of 5alpha reduction by finasteride or dutasteride and food intake in men.
Amory JK; Page ST; Bremner WJ
J Androl; 2006; 27(1):72-8. PubMed ID: 16400081
[TBL] [Abstract][Full Text] [Related]
11. Sublingual administration of testosterone-hydroxypropyl-beta-cyclodextrin inclusion complex simulates episodic androgen release in hypogonadal men.
Stuenkel CA; Dudley RE; Yen SS
J Clin Endocrinol Metab; 1991 May; 72(5):1054-9. PubMed ID: 1902483
[TBL] [Abstract][Full Text] [Related]
12. Serum LH concentrations in hypogonadal men during transdermal testosterone replacement through scrotal skin: further evidence that ageing enhances testosterone negative feedback. The Testoderm Study Group.
Winters SJ; Atkinson L
Clin Endocrinol (Oxf); 1997 Sep; 47(3):317-22. PubMed ID: 9373453
[TBL] [Abstract][Full Text] [Related]
13. Testosterone substitution normalizes elevated serum leptin levels in hypogonadal men.
Jockenhövel F; Blum WF; Vogel E; Englaro P; Müller-Wieland D; Reinwein D; Rascher W; Krone W
J Clin Endocrinol Metab; 1997 Aug; 82(8):2510-3. PubMed ID: 9253326
[TBL] [Abstract][Full Text] [Related]
14. Serum androgen bioactivity during 5alpha-dihydrotestosterone treatment in elderly men.
Raivio T; Tapanainen JS; Kunelius P; Jänne OA
J Androl; 2002; 23(6):919-21. PubMed ID: 12399539
[TBL] [Abstract][Full Text] [Related]
15. A ten-year safety study of the oral androgen testosterone undecanoate.
Gooren LJ
J Androl; 1994; 15(3):212-5. PubMed ID: 7928661
[TBL] [Abstract][Full Text] [Related]
16. Comparative pharmacokinetics of three doses of percutaneous dihydrotestosterone gel in healthy elderly men--a clinical research center study.
Wang C; Iranmanesh A; Berman N; McDonald V; Steiner B; Ziel F; Faulkner SM; Dudley RE; Veldhuis JD; Swerdloff RS
J Clin Endocrinol Metab; 1998 Aug; 83(8):2749-57. PubMed ID: 9709942
[TBL] [Abstract][Full Text] [Related]
17. A safety study of administration of parenteral testosterone undecanoate to elderly men over minimally 24 months.
Haider A; Gooren LJ; Padungtod P; Saad F
Andrologia; 2010 Dec; 42(6):349-55. PubMed ID: 21105885
[TBL] [Abstract][Full Text] [Related]
18. In older men an optimal plasma testosterone is associated with reduced all-cause mortality and higher dihydrotestosterone with reduced ischemic heart disease mortality, while estradiol levels do not predict mortality.
Yeap BB; Alfonso H; Chubb SA; Handelsman DJ; Hankey GJ; Almeida OP; Golledge J; Norman PE; Flicker L
J Clin Endocrinol Metab; 2014 Jan; 99(1):E9-18. PubMed ID: 24257908
[TBL] [Abstract][Full Text] [Related]
19. Transdermal dihydrotestosterone treatment of 'andropause'.
de Lignieres B
Ann Med; 1993 Jun; 25(3):235-41. PubMed ID: 7687444
[TBL] [Abstract][Full Text] [Related]
20. Serum testosterone and bioavailable testosterone correlate with age and body size in hypogonadal men treated with testosterone undecanoate (1000 mg IM--Nebido).
Moisey R; Swinburne J; Orme S
Clin Endocrinol (Oxf); 2008 Oct; 69(4):642-7. PubMed ID: 18394021
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
